Recommendation to Pause Use of Johnson & Johnson’s Janssen COVID-19 Vaccine

 Recommendation to Pause Use of Johnson & Johnson’s Janssen COVID-19 Vaccine

Since use of COVID-19 vaccines began in the United States, scientists and doctors have been monitoring reports of vaccine side effects and adverse events. Results from monitoring the J&J/Janssen COVID-19 vaccine indicate that the most frequently reported side effects are headache, fever, chills, injection site pain, and fatigue. These side effects usually start within a day or two of getting the vaccine. Side effects might affect the ability to do daily activities, but they usually go away in a few days.

Some people have reported fainting events (fainting and near-fainting) after J&J/Janssen vaccination. These events happened during the recommended 15-minute wait after vaccination. It’s not clear at this time whether these events were associated with the vaccine itself or with anxiety about vaccination. Concerns about needles or shots may have led some people to choose the one-dose J&J/Janssen COVID-19 vaccine.

Reports also suggest an increased risk of TTS after vaccination with the J&J/Janssen COVID-19 vaccine. The Vaccine Adverse Event Reporting System (VAERS) reports show that symptoms of TTS started between 3 and 15 days after vaccination. TTS is a rare adverse event. For women ages 50 years and older and men of all ages, this adverse event is even more rare. View the latest update of total confirmed TTS cases following J&J/Janssen COVID-19 vaccine.

CDC and FDA are monitoring reports of Guillain-Barré Syndrome (GBS) in people who have received the J&J/Janssen COVID-19 vaccine. GBS is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. Most people fully recover from GBS, but some have permanent nerve damage. Preliminary reports of GBS have been identified in VAERS (see Selected Adverse Events page for latest counts). These cases have largely been reported about 2 weeks after vaccination and mostly in men, many 50 years and older. CDC will continue to monitor and evaluate reports of GBS happening after COVID-19 vaccination and will share more information as it becomes available.

Leave a Reply

Your email address will not be published. Required fields are marked *